Probiotics: Benefits, Best Strains, Dosing, and Side Effects

Table of Contents

• Overview
• Forms and Delivery
• Evidence for Health Benefits
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary Sources
• References

Overview

Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host [1]. This definition, established by the International Scientific Association for Probiotics and Prebiotics (ISAPP), distinguishes probiotics from the many "live culture" products that have not demonstrated health benefits in controlled trials. Most probiotic organisms are bacteria — primarily from the genera Lactobacillus (now reclassified into several genera within the family Lactobacillaceae), Bifidobacterium, Streptococcus, Enterococcus, Escherichia, and Bacillus — though the yeast Saccharomyces boulardii is also widely used [1][2].

Probiotics should not be confused with prebiotics, which are typically complex carbohydrates (such as inulin and fructo-oligosaccharides) that serve as metabolic fuel for beneficial gut microorganisms [3]. Products containing both prebiotics and probiotics are called synbiotics. Nor should probiotics be confused with postbiotics — preparations of dead or fragmented microorganisms, with or without their metabolites, that confer a health benefit [4].

The Gut Microbiome

The human gastrointestinal tract is colonized by trillions of microorganisms — bacteria, archaea, viruses, fungi, and protozoa — collectively known as the gut microbiota or microbiome [2]. The composition and activity of this microbial community profoundly influences human health, affecting digestion, nutrient absorption, immune function, metabolic regulation, and even neurological signaling via the gut-brain axis.

Probiotics are consumed orally and exert their effects primarily in the gastrointestinal tract, where they may transiently colonize the gut mucosa in highly individualized patterns depending on the baseline microbiota, the probiotic strain used, and the region of the GI tract [5]. This means the same probiotic may work differently in different individuals — a critical point that helps explain the variability seen in clinical trials.

Mechanisms of Action

Probiotics exert health benefits through multiple mechanisms, some shared broadly across species and others unique to specific strains [1][2]:

• Nonspecific mechanisms (shared across many strains): Inhibition of pathogenic microorganism growth via colonization resistance and antimicrobial substance production; improvement of intestinal transit; production of short-chain fatty acids (SCFAs); reduction of luminal pH in the colon
• Species-specific mechanisms: Vitamin synthesis, gut barrier reinforcement, bile salt metabolism, enzymatic activity, and toxin neutralization
• Strain-specific mechanisms: Cytokine production, specific immunomodulatory activities, and effects on the endocrine and nervous systems

Because effects can be strain-specific, recommendations for probiotic use need to be strain-specific — and researchers should account for strain differences when designing studies and pooling data [2][6][7].

Strain Nomenclature

Probiotics are identified by their genus, species, subspecies (if applicable), and an alphanumeric strain designation [2]. For example:

Genus	Species	Subspecies	Strain	Common Name
Lacticaseibacillus (formerly Lactobacillus)	rhamnosus	—	GG	LGG
Bifidobacterium	animalis	lactis	DN-173 010	Bifidus regularis
Bifidobacterium	longum	longum	35624	Bifantis
Saccharomyces	boulardii	—	CNCM I-745	—

In 2020, the Lactobacillus genus was restructured into 23 novel genera, though many products and studies still use the older nomenclature [8]. This article uses the genus names that were in use at the time each study was conducted.

Why Strain Specificity Matters

A key principle in probiotic science is that benefits demonstrated for one strain cannot be assumed to apply to another strain of the same species. Lactobacillus rhamnosus GG has different clinical effects than Lactobacillus rhamnosus R0011, even though both belong to the same species. An analysis of 65 clinical trials found that multi-strain mixtures containing at least one individually-tested strain tended to be comparable to — but not necessarily better than — the single effective strain for most conditions [9]. Exceptions exist: a combination of L. rhamnosus GG and B. lactis appeared more effective than L. rhamnosus GG alone for H. pylori eradication, while L. rhamnosus combined with B. lactis strains was less effective than LGG alone for necrotizing enterocolitis prevention [9].

Forms and Delivery

Supplement Forms

Probiotic supplements are available as capsules, tablets, powders, liquids, chewables, gummies, and sachets. They may contain a single strain or multiple strains. The number of viable cells is measured in colony-forming units (CFU). Many products contain 1 to 10 billion CFU per dose, though some contain 50 billion CFU or more [2][10].

Higher CFU counts are not necessarily more effective. The optimal dose depends entirely on the specific strain and the condition being targeted. Some strains are effective at as little as 50 million CFU per day (e.g., L. reuteri DSM 17938 for infant colic), while others require over 1 trillion CFU for clinical benefit [11][12].

Label Reading

Current FDA labeling regulations only require manufacturers to list the total weight of microorganisms on the Supplement Facts panel — this weight includes both live and dead organisms and has no relationship to the number of viable cells [13]. Manufacturers may voluntarily list CFU counts. Consumers should look for products labeled with CFU at the end of the product's shelf life (the "Best By" date), not at the time of manufacture, because probiotics can die during storage [14].

The International Scientific Association for Probiotics and Prebiotics (ISAPP) advises manufacturers to list total CFU — ideally for each strain — through the expiration date [15]. Products that state amounts only "at time of manufacture" should be viewed with caution, though FDA regulations require that stated amounts still be present at time of use if the product is consumed before its expiration date [14].

Survival Through the GI Tract

For a probiotic to exert its effects, the organisms generally must survive passage through stomach acid and reach the intestines alive. Survival depends on the species and formulation:

• *Most Lactobacillus, Bifidobacterium, and Streptococcus species* can survive stomach acid passage without enteric coating, though only an estimated 10-20% of organisms survive when taken without food. Enteric coating can increase survival several-fold [16][17].
• Taking probiotics with or just before a meal containing some fat substantially improves survival through stomach acid, as the food buffers gastric pH and slows transit [18].
• Spore-forming bacteria (e.g., Bacillus coagulans) naturally form a protective spore coat that resists harsh GI conditions. These are sometimes marketed as having superior survivability [12].
• Yeast-based probiotics (Saccharomyces boulardii) are inherently resistant to gastric acid and do not require special formulation for GI survival [12].
• Heat sensitivity: Most probiotics are killed by heat. However, Bacillus coagulans GBI-30 spores can survive heating in water at 85 degrees C (185 degrees F) for 3 minutes, though viability is lost at boiling temperature (100 degrees C / 212 degrees F) [19]. There is no evidence that other probiotic species remain viable in hot water.

Storage Requirements

Storage requirements depend on the organism, formulation, and packaging:

• Most probiotic supplements should be kept away from heat, light, and moisture. After opening, moisture exposure can activate dormant organisms prematurely, leading to their death [12].
• Some products require refrigeration; others are shelf-stable at room temperature. Always follow label instructions.
• Probiotic yeast (S. boulardii) and spore-forming bacteria (B. coagulans) generally do not require refrigeration [12].
• Blister packs provide better moisture protection than bottles of loose capsules.

Fermented Food Sources

Some fermented foods are natural sources of beneficial microorganisms, though not all fermented foods contain proven probiotic strains [20]:

• Yogurt is made using Lactobacillus bulgaricus and Streptococcus thermophilus as starter cultures. Some yogurts also contain added probiotic strains from Bifidobacterium or Lactobacillaceae. Look for labels stating "live and active cultures" — products labeled merely "live cultures" may contain organisms added for texture rather than health benefits [20].
• Kefir is a fermented milk drink containing diverse communities of bacteria and yeast.
• Fermented foods with live cultures but without proven probiotic strains include many cheeses, kimchi, kombucha, sauerkraut, miso, pickles, and raw unfiltered apple cider vinegar [21].
• Some fermented foods lose their live cultures during processing — for example, sourdough bread and most commercially pickled vegetables are heated after fermentation and contain no live organisms when consumed.

Kombucha: Special Considerations

Kombucha is a fermented tea containing live microorganisms, small amounts of alcohol (typically less than 0.5% ABV, though some commercial products have been found to contain up to 2.5%), and various acids [22]. Key considerations:

• Kombucha must be refrigerated at all times. At warm temperatures, fermentation continues rapidly and can cause excess carbonation or bottle explosions [22].
• Since January 2021, FDA labeling rules require that sugar present after fermentation be listed as "Sugars" while sugar used for fermentation or added for flavoring be listed as "Added Sugars" [12].
• Pathogenic bacteria can form in kombucha that is not properly made or stored. Several cases of lactic acidosis and metabolic acidosis, some fatal, have been associated with home-made kombucha [23].
• Laboratory studies suggest kombucha may cause tooth enamel erosion due to its low pH (2.82-3.66) and the types of acids present — releasing more than 7 times as much calcium from model tooth enamel as cola beverages [24].
• Women who are pregnant or breastfeeding, and people with weakened immune systems, should avoid kombucha or consult a physician before consuming it [12][23].

How Long Do Probiotics Persist?

Probiotics generally survive only a few days to about 3 weeks in the GI tract after supplementation is stopped [25][26]. For ongoing benefits, probiotics should be taken continuously, or for the duration indicated by clinical studies for a specific condition.

Evidence for Health Benefits

Irritable Bowel Syndrome (IBS)

IBS is a common functional gastrointestinal disorder characterized by recurrent abdominal pain, bloating, and altered bowel habits. Growing evidence implicates the gut microbiota in IBS pathophysiology — proinflammatory species such as Enterobacteriaceae are overrepresented in IBS patients, who typically also have reduced populations of Lactobacillus and Bifidobacterium [27][28].

Overall efficacy: A meta-analysis of 23 RCTs in 2,575 patients found that probiotics reduced the risk of persistent IBS symptoms by 21% [29]. Various species showed beneficial effects on global symptoms, abdominal pain, bloating, and flatulence, though study quality was generally low. A second meta-analysis of 15 RCTs (n=1,793) found that probiotics reduced overall symptom severity and abdominal pain more than placebo after 8-10 weeks; in children, probiotics also improved mucosal barrier function [30].

Multi-strain vs single-strain: A systematic review of 35 RCTs evaluating 16 single-strain and 19 multi-strain products in 3,406 adults with IBS found that multi-strain products were more likely to produce clinically meaningful improvements. Of the studies finding significant global symptom reduction (14 of 29 trials) or clinically meaningful pain reduction (8 of 34 trials), most used multi-strain products. Only trials of multi-strain products found clinically meaningful improvement in quality of life [31][32].

Strain-specific effects: In a meta-analysis of 10 RCTs (n=877 adults), probiotics containing Bifidobacterium breve, B. longum, or Lactobacillus acidophilus species significantly lowered pain scores compared to placebo [33]. In contrast, Streptococcus thermophilus, B. animalis, B. infantis, L. casei, L. plantarum, L. bulgaricus, and S. boulardii had no significant effect on pain. Flatulence improved with all tested probiotics, and abdominal distension improved with B. breve, B. infantis, L. casei, or L. plantarum species [33].

Specific strains with clinical evidence for IBS:

• Bifidobacterium infantis 35624: 100 million to 1 billion CFU daily reduced abdominal pain, bloating, and bowel movement difficulty in adult women (but did not reduce bowel movement frequency) [34].
• Symprove (4-strain combination of L. rhamnosus NCIMB30174, L. plantarum NCIMB30173, L. acidophilus NCIMB30175, Enterococcus faecium NCIMB30176): 10 billion organisms per 50 mL daily reduced pain and improved bowel habits but not bloating or overall quality of life [35].
• VSL#3/Visbiome (8-strain combination, 450 billion organisms from Bifidobacterium, Lactobacillus, and Streptococcus genera): Has shown benefit for IBS, though the formula currently sold as VSL#3 may differ from the formula used in original studies [36].
• Saccharomyces cerevisiae CNCM I-3856: 4 billion CFU daily reduced abdominal pain and discomfort after 4 weeks [37].
• Bacillus coagulans MTCC 5856: 2 billion spores daily (taken at least 30 minutes before breakfast) decreased many symptoms in diarrhea-predominant IBS when combined with standard medical treatment [38].
• Lactobacillus rhamnosus GG: 3 billion CFU twice daily reduced frequency and severity of pain in children [39]. In children with functional abdominal pain, Lactobacillus reuteri DSM 17938 at 200 million CFU daily reduced pain intensity [40].

Antibiotic-Associated Diarrhea (AAD)

Antibiotics disrupt the intestinal microbiome, reducing microbial diversity, which can lead to osmotic diarrhea, loss of colonization resistance, and increased intestinal motility [41]. Up to 30% of patients on antibiotics develop AAD [42]. Inpatients, children under 2, and adults over 65 are at highest risk [41][42].

Overall risk reduction: Meta-analyses indicate that specific probiotic strains may reduce the risk of AAD by approximately 51% [43]. However, benefits depend on the type of antibiotic, the probiotic strain, patient age, and care setting. Probiotics have been associated with reduced AAD risk in children and adults aged 18-64 but not in adults over 65 [44].

LGG for AAD: A systematic review and meta-analysis of 12 RCTs (n=1,499 children and adults) found that LGG at 4 x 10^8 to 12 x 10^10 CFU for 10 days to 3 months reduced AAD risk from 22.4% to 12.3% [45]. When children and adults were analyzed separately, the difference was statistically significant only in children. The dose of 1-2 x 10^10 CFU/day reduced AAD risk in children by 71% [45]. Starting probiotics within 2 days of the first antibiotic dose is more effective than starting later.

Saccharomyces boulardii for AAD: A systematic review and meta-analysis of 21 RCTs (n=4,780 adults and children aged 6 months to 65 years) found that S. boulardii reduced AAD risk in adults from 17.4% to 8.2% and in children from 20.9% to 8.8% compared to placebo [46]. Various doses were tested with no clear dose-dependent effect.

Other effective combinations for AAD:

• L. acidophilus CL1285 and L. casei LBC80R: 50-100 billion CFU reduced AAD incidence [47].
• HOWARU Restore (L. acidophilus NCFM, L. paracasei Lpc-37, B. lactis Bi-07, and B. lactis Bl-04 in equal parts): 17 billion CFU daily was effective [48].
• S. boulardii: 500 mg twice daily during antibiotic treatment and for one week afterward reduced AAD [49].
• Lacidofil Strong (L. rhamnosus R0011 and L. helveticus R0052): 3.8 billion and 200 million CFU respectively, twice daily, shortened diarrhea duration in adults [50].

Guideline positions: ESPGHAN (2023) recommends administering LGG or S. boulardii at 5 x 10^9 CFU/day or more starting simultaneously with antibiotics to prevent AAD in children with risk factors [51]. There is no evidence that using more than one probiotic strain provides additional benefit over effective single strains [2][45].

Timing and antibiotic interaction: Probiotics should be started on the first day of antibiotic treatment and continued for 1-2 weeks after completion. It may be advisable to take probiotics and antibiotics at least 2 hours apart to reduce the possibility of the antibiotic killing the probiotic organisms [12]. One study suggested that probiotic supplementation during antibiotic treatment can delay restoration of normal gut bacteria after antibiotic cessation [52].

Atopic Dermatitis (Eczema)

Atopic dermatitis is the most common form of eczema, affecting 15-20% of children and 1-3% of adults worldwide [53]. Probiotics have been evaluated for both prevention and treatment.

Prevention: A 2018 meta-analysis of 27 RCTs and one controlled cohort study (n=6,907 infants and children) found that probiotic treatment during pregnancy and infancy significantly reduced the risk of atopic dermatitis from 34.7% to 28.5% between ages 6 months and 9 years [54]. Key findings:

• Using probiotics during both prenatal and postnatal periods significantly reduced incidence; using them during only one period did not
• L. rhamnosus and L. paracasei significantly reduced incidence, whereas L. reuteri and L. acidophilus did not

In contrast, a meta-analysis of 5 RCTs (n=889) found that LGG supplementation specifically did not reduce eczema risk in children up to age 4 years, regardless of whether given directly to children or via maternal supplementation [55].

Treatment: A meta-analysis of 13 RCTs (n=1,070 participants age 18 or younger) found that 4-8 weeks of probiotic treatment significantly reduced SCORAD scores (a measure of eczema severity) [56]. However:

• Benefits were seen in children aged 1-18 years but not in infants younger than 1 year
• Lactobacillus, L. fermentum, and multi-strain mixtures reduced SCORAD values, while LGG and L. plantarum had no effect

Another meta-analysis of 8 RCTs (n=741 participants from birth to 36 months) found that Lactobacillus-containing probiotics reduced symptom severity in infants and toddlers, but Bifidobacterium-containing probiotics did not. Treatment significantly improved moderate-to-severe disease but not mild forms [57].

A Cochrane Review of 39 RCTs (n=2,599 participants aged 1-55 years) concluded that while probiotics might slightly reduce SCORAD scores, the differences were not clinically significant. The reviewers concluded that current evidence does not support the use of probiotics for eczema treatment [58].

Practical guidance for eczema prevention: 10 billion CFU daily of LGG to pregnant mothers for 4 weeks before expected delivery and to infants for 6 months may reduce eczema risk and, possibly, the risk of neuropsychiatric disorders later in childhood [59]. Alternatively, 6 billion CFU daily of L. rhamnosus HN001 (HOWARU Rhamnosus) from week 35 of pregnancy to 6 months postpartum, and to infants from birth to age 2 years, has reduced eczema risk [60].

Pediatric Acute Infectious Diarrhea

Acute diarrhea (loose stools with at least 3 episodes in 24 hours) is common in children and usually self-limiting [61]. A 2020 Cochrane Review of 82 RCTs (n=12,127, primarily children) found that probiotics reduced the risk of diarrhea lasting 48 hours or more by 36% and reduced mean diarrhea duration by 21.3 hours [62]. However, when only low-risk-of-bias studies were included, the benefit disappeared.

Specific strains:

• LGG: An assessment of 11 RCTs (n=2,444) showed LGG is most effective for infectious diarrhea at a daily dose of at least 10^10 CFU, reducing diarrhea duration by approximately 1 day [63][64].
• Saccharomyces boulardii: A review of 22 trials (n=2,440 children aged 1 month to 15 years) found that S. boulardii (most commonly 10^9 to 10^10 CFU/day for 5-10 days) reduced diarrhea duration and stool frequency, also by approximately 1 day [65].

However, two large RCTs in pediatric emergency departments (combined n=1,729) found that a 5-day course of LGG was no better than placebo for acute gastroenteritis in developed countries [66][67]. This may reflect that most episodes in developed countries are self-limiting and require only rehydration therapy.

Guideline disagreement: ESPGHAN (2023) recommends LGG, S. boulardii, L. reuteri, or L. rhamnosus + L. reuteri combinations for pediatric acute gastroenteritis, though the grade of recommendation is weak and certainty of evidence low [51]. In contrast, the AGA (2020) recommended against probiotic use for acute infectious gastroenteritis in children in the United States and Canada, citing concerns about bias in positive studies (mostly conducted in India, Italy, Poland, Turkey, and Pakistan) [68].

Rotaviral diarrhea: Doses of up to 10 billion CFU of LGG or L. reuteri may significantly reduce the diarrheal phase in infants and children up to age 3 [12].

Traveler's diarrhea: 2 billion CFU of LGG daily, starting 2 days before travel and continuing throughout the trip, may reduce the likelihood of traveler's diarrhea [69]. S. boulardii 250-1,000 mg daily, started 5 days before travel, may also be protective, with larger doses possibly more effective [70].

Inflammatory Bowel Disease (IBD)

IBD encompasses ulcerative colitis and Crohn's disease — chronic inflammatory conditions likely caused by a combination of genetic and environmental factors, including immune dysfunction [68]. Researchers have investigated whether probiotics can help manage IBD given the alterations in gut microbiome observed in these patients [68].

Ulcerative colitis: A 2020 AGA systematic review examined 17 trials using various probiotic formulations in 1,673 children and adults [68]. There is some evidence that probiotics may modestly reduce disease activity in mild-to-moderate ulcerative colitis when combined with conventional therapies. A 2020 Cochrane Review of 14 studies (n=865) indicated that probiotics may help induce remission and that combining probiotics with 5-ASA may be superior to 5-ASA alone, though evidence was limited and of low certainty [71]. A separate Cochrane Review of 12 studies (n=1,473) found the effects on maintaining remission uncertain due to small study sizes [72].

Crohn's disease: The same AGA review examined 12 trials in 689 children and adults and found no evidence that probiotics help induce or maintain remission in Crohn's disease [68].

Clinical guidelines: AGA recommends using probiotics in adults and children with ulcerative colitis or Crohn's disease only in the context of clinical trials [68]. The British Society of Gastroenterology (2019) concluded that while probiotics may be modestly beneficial for ulcerative colitis, they should not be routinely used, and found no evidence of benefit for Crohn's disease [73]. ESPGHAN (2023) stated insufficient evidence to recommend for or against probiotics in pediatric IBD [51].

Cholesterol and Cardiovascular Risk

Probiotics may reduce cholesterol through several mechanisms: increasing bile salt hydrolase activity (which increases bile acid synthesis and thus reduces serum cholesterol), binding cholesterol in the small intestine to reduce absorption, incorporating cholesterol into bacterial cell membranes, and producing short-chain fatty acids that modulate hepatic cholesterol metabolism [74][75][76].

Meta-analysis evidence: A meta-analysis of 30 RCTs (n=1,624, mostly adults) found that 3-12 weeks of probiotic use reduced total cholesterol by a mean of 7.8 mg/dL and LDL cholesterol by 7.3 mg/dL versus placebo [77]. Benefits were slightly greater in studies lasting 8 or more weeks and in participants with baseline total cholesterol above 240 mg/dL. Among strains included in more than three studies, L. acidophilus, a mixture of L. acidophilus and B. lactis, and L. plantarum were associated with significant reductions, while L. helveticus and E. faecium were not.

A smaller meta-analysis of 11 RCTs (n=602 adults) found 6.6 mg/dL lower total cholesterol and 8.5 mg/dL lower LDL cholesterol with probiotic use, with no significant effect on HDL [78]. Effects were most pronounced with treatment longer than 4 weeks, in those with hypercholesterolemia, and in those aged 45 or older.

A review focusing on multi-strain vs single-strain products found that multi-strain probiotics produced statistically significant reductions in total cholesterol (12.0 mg/dL) and LDL cholesterol (20.1 mg/dL), while single-strain products did not [79]. However, a review of 14 studies in 942 healthy adults found insufficient evidence that probiotics improve blood lipid levels [80].

Specific strains with cholesterol-lowering evidence:

• Lactobacillus reuteri NCIMB 30242: 2 billion CFU with breakfast and dinner [81]
• Enterococcus faecium M-74: 2 billion CFU daily [12]
• L. acidophilus La5 + B. lactis BB-12: 1.2 billion CFU each [82]
• L. curvatus HY7601 + L. plantarum KY1032: 5 billion CFU each (reduced both LDL and triglycerides) [83]
• L. fermentum ME-3: 8 billion CFU (reduced LDL and triglycerides) [84]

Obesity and Weight Management

The gut microbiota plays an important role in nutrient and energy extraction from food. Research in mice suggests the gut microbiome affects energy expenditure and storage, though whether these effects translate to humans is uncertain [85].

Clinical evidence has been mixed:

• Lactobacillus gasseri SBT2055 (LG2055): An RCT of 210 adults with high visceral fat found that 12 weeks of fermented milk containing 10^7 or 10^6 CFU/g produced significant reductions in visceral fat area (8.5% and 8.2% respectively), BMI, waist and hip circumference, and body fat mass versus control [86]. Doses of 1.4, 16, or 100 billion CFU daily appear to have similar effects, except that lower doses (1.4 or 16 billion) may not provide the same subcutaneous fat loss as the higher dose [12][87].
• Lactobacillus rhamnosus CGMCC1.3724: An RCT (n=125 adults with obesity) found that 3.24 x 10^8 CFU daily for 24 weeks combined with energy restriction did not significantly affect weight loss overall, but female participants lost significantly more weight (1.8 kg at 12 weeks, 2.6 kg at 24 weeks) than placebo [88]. In obese women specifically, a dose of 162 million CFU daily with 300 mg prebiotic (oligofructose and inulin) showed benefit [12].
• Bifidobacterium breve B-3: 50 billion CFU daily as a capsule appeared to cause a small reduction in body fat in overweight Japanese adults [89].

Systematic review findings:

• A 2017 systematic review of 14 trials (n=1,067 individuals with overweight or obesity) found that probiotics (mostly Lactobacillus) significantly decreased body weight and/or body fat in 9 trials, had no effect in 3, and increased body weight in 2 [90].
• A meta-analysis of 15 RCTs (n=957) found that probiotics reduced body weight by 0.6 kg, BMI by 0.27 kg/m^2, and fat percentage by 0.6% versus placebo — effects that were small and of questionable clinical significance [91].
• A more recent meta-analysis of 19 trials (n=1,412) found probiotics/synbiotics reduced waist circumference slightly (by 0.82 cm) but had no effect on body weight or BMI [92].
• Another meta-analysis of 14 adult trials, 5 child trials, and 12 infant trials found probiotics promoted a mean loss of 0.54 kg in adults, a gain of 0.20 kg in children, and no significant change in infants [93].

Synthesis: Effects of probiotics on body weight are small and depend on the strain, dose, duration, and patient characteristics. Current evidence does not support probiotics as a meaningful weight loss intervention, though specific strains may produce modest reductions in body fat when combined with dietary changes.

Upper Respiratory Tract Infections (Colds and Flu)

Adults: 1 billion CFU daily of a combination of L. plantarum HEAL 9 (DSM 15312) and L. paracasei 8700:2 (DSM 13434) for 12 weeks during cold season reduced the incidence and duration of colds in one study [94], though not all studies using this combination have replicated the benefit [95].

Children: A combination of L. acidophilus NCFM (2.5 billion CFU) and B. animalis subsp. lactis Bi-07 (2.5 billion CFU), taken as a powder mixed with milk twice daily during colder months, reduced cold and flu symptoms in children [96]. When started as soon as a household member became sick, a daily dose of L. acidophilus DDS-1 (1 billion CFU) and B. lactis UABLA-12 (4 billion CFU) with a fructooligosaccharide prebiotic (50 mg) reduced the severity of acute respiratory infections caught by children [97].

Throat infections in children: A lozenge containing 1 billion CFU of S. salivarius K12 taken daily for three months significantly reduced the occurrence of streptococcal and viral throat infections in children [98].

Mental Health: Anxiety and Depression

Anxiety: 3 billion CFU of B. longum R0175 with L. helveticus R0052 taken daily with breakfast for 30 days showed anxiolytic effects [99].

Depression: A multi-strain powder containing a total of 5 billion CFU from two Bifidobacterium strains (B. bifidum W23, B. lactis W52) and five Lactobacillus strains (L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, L. lactis W19 and W58), taken mixed with water or lukewarm milk before bed, reduced negative thoughts associated with sadness in a 4-week study [100].

The evidence for probiotic effects on mental health remains preliminary and largely limited to individual small studies. While the gut-brain axis provides a plausible mechanism, well-designed large-scale RCTs are needed to confirm these findings.

Migraine

A 14-strain probiotic (Bio-Kult) was found to reduce migraine frequency and severity in people with episodic or chronic migraine [12]. However, this is a single finding and should not be considered definitive. The relationship between fermented dairy products and migraine is complex — fermented cheeses may trigger migraines via tyramine and histamine, though the connection is not well established [101]. The National Headache Foundation recommends that people with migraine avoid fermented foods and limit yogurt consumption to half a cup per day [102].

Diverticular Disease

Adding a probiotic to standard drug therapy has reduced the recurrence of symptoms in diverticular disease. Effective regimens include L. casei subsp. DG at 24 billion organisms daily [103] or L. reuteri ATCC PTA 4659 at 500 million organisms twice daily [104].

Vaginal Health

One capsule daily containing over 1 billion viable cells each of L. rhamnosus GR-1 and L. reuteri RC-14, taken orally, has been shown to reduce colonization of the vagina by potentially pathogenic bacteria and yeast [105].

Periodontitis

A lozenge containing 100 million CFU each of L. reuteri DSM17938 and L. reuteri ATCC PTA5289 (Prodentis), taken twice daily after dental scaling, may be helpful in moderate-to-severe periodontitis [106].

Mastitis

90 billion CFU of either L. fermentum CECT5716 or L. salivarius CECT5713, taken daily for 21 days, has been shown to reduce breast pain, resolve infection, and reduce recurrence in nursing mothers with mastitis [107].

Allergy

2 billion CFU of L. paracasei LP-33 daily may reduce the impact of allergy symptoms on quality of life in people with grass pollen allergy already taking an antihistamine (loratadine 10 mg) [108].

Necrotizing Enterocolitis (NEC) in Preterm Infants

NEC is a life-threatening gastrointestinal illness primarily affecting preterm infants with very low birth weight (less than 1,500 g) [109]. Certain probiotics can block inflammatory signaling pathways in intestinal cells and strengthen the gut barrier [109][110][111][112].

Evidence: A 2020 AGA technical review of 63 trials (n=15,712 preterm infants) found that specific combinations of Lactobacillus and Bifidobacterium strains reduced the risk of all-cause mortality, severe NEC, and time to full enteral feeds [68]. A 2023 systematic review of 90 trials confirmed that multi-strain probiotics reduce mortality, severe NEC, feeding intolerance, and hospitalization duration [113]. However, a Cochrane Review stated the evidence is inconclusive for very preterm infants (born before 32 weeks) and very low birth weight infants (less than 1,500 g) [114].

Guidelines: ESPGHAN (2023) recommends LGG (1-6 x 10^9 CFU) or the combination of B. infantis, B. lactis, and S. thermophilus (3.0-3.5 x 10^8 CFU per strain) for NEC prevention in preterm infants, though grade of recommendation is weak and certainty of evidence is low [51]. AGA recommends specific Lactobacillus-Bifidobacterium combinations for preterm, low-birth-weight infants [68]. The WHO (2023) states probiotics may be considered for human-milk-fed preterm infants born before 32 weeks gestation [115].

FDA safety concern: In 2023, the FDA issued a press release warning that administering probiotics to preterm infants may cause infection or potentially fatal disease. Probiotics have been associated with one infant death and more than two dozen adverse events in recent years, and the agency emphasized that probiotics have not undergone FDA premarket review for medical uses [116].

PPI-Induced Bloating

12 billion CFU of L. paracasei F19, taken twice daily three times a week, prevented bloating and flatulence occurring with continued proton pump inhibitor use [117].

Chemotherapy-Induced Diarrhea

10-20 billion CFU of LGG daily has been shown to reduce diarrhea associated with chemotherapy [118].

Recommended Dosing

Probiotic dosing is inherently strain-specific. There is no universal "optimal dose" — the effective dose depends entirely on the specific organism and the target condition. The following table summarizes evidence-based dosing for the most well-studied applications:

Dosing Summary Table

Condition	Strain(s)	Dose (CFU/day)	Duration	Evidence Level
AAD prevention (children)	LGG	1-2 x 10^10	Duration of antibiotics + 1-2 weeks	Moderate
AAD prevention (adults)	S. boulardii	500 mg (approx. 5 x 10^9) twice daily	Duration of antibiotics + 1 week	Moderate
AAD prevention	L. acidophilus CL1285 + L. casei LBC80R	50-100 x 10^9	Duration of antibiotics	Moderate
IBS (adults)	B. infantis 35624	10^8 to 10^9	Ongoing	Moderate
IBS (adults)	VSL#3/Visbiome (8-strain)	450 x 10^9	Ongoing	Moderate
IBS (children)	LGG	3 x 10^9 twice daily	Ongoing	Moderate
Infant colic	L. reuteri DSM 17938	10^8 (drops)	Ongoing	Low-Moderate
Eczema prevention	LGG or L. rhamnosus HN001	6-10 x 10^9	Prenatal + postnatal (6-24 months)	Moderate
Cold/flu (adults)	L. plantarum HEAL 9 + L. paracasei 8700:2	10^9	12 weeks during cold season	Low-Moderate
Cold/flu (children)	L. acidophilus NCFM + B. lactis Bi-07	5 x 10^9	During colder months	Low-Moderate
Cholesterol lowering	L. reuteri NCIMB 30242	2 x 10^9 (with breakfast + dinner)	8+ weeks	Low-Moderate
Traveler's diarrhea	LGG	2 x 10^9	2 days before + during travel	Low
Traveler's diarrhea	S. boulardii	250-1,000 mg daily	5 days before + during travel	Low
Anxiety	B. longum R0175 + L. helveticus R0052	3 x 10^9	30 days	Low
Vaginal health	L. rhamnosus GR-1 + L. reuteri RC-14	More than 10^9 each	Ongoing	Low-Moderate
Periodontitis	L. reuteri DSM17938 + ATCC PTA5289	10^8 each (lozenge, twice daily)	After dental scaling	Low
NEC prevention (preterm infants)	LGG or B. infantis + B. lactis + S. thermophilus	1-6 x 10^9 (LGG) or 3-3.5 x 10^8 per strain	During NICU stay	Moderate (but safety concerns)

General Dosing Principles

• Most conditions: 1-10 billion CFU per day is the typical effective range, though some conditions require higher doses (e.g., 450 billion for VSL#3 in IBS) and others respond to lower doses (e.g., 50-200 million for L. reuteri in infant colic) [2][12].
• Timing: Take with or just before a meal containing some fat for optimal survival through stomach acid [18]. For AAD prevention, start within 2 days of the first antibiotic dose [45]. Take probiotics at least 2 hours apart from antibiotics [12].
• Duration: Probiotics persist only days to weeks after discontinuation [25][26]. For general gut health, ongoing daily use is required. For condition-specific use, follow the duration used in clinical trials (typically 4-12 weeks).
• There is no good clinical evidence that taking probiotics at the same time as vitamins or minerals affects the absorption or effects of either [12]. However, because yogurt and kefir can contain significant calcium, it is best not to take a calcium supplement at the same time as consuming these dairy probiotics (the body can only absorb about 500 mg of calcium at once) [12].

Product Selection Guidance

The World Gastroenterology Organisation (WGO) recommends that clinicians only advise patients to use probiotic strains, doses, and durations that have been shown beneficial in human studies [2]. When selecting a product:

1. Match the strain to the condition. A probiotic proven for AAD prevention may have no effect on IBS. 2. Look for specific strain designations (e.g., L. rhamnosus GG, not just "Lactobacillus rhamnosus"). Products using unspecified strains may not provide the same benefits as those used in research. 3. Check CFU at expiration, not at manufacture. Products should guarantee CFU counts through the "Best By" date. 4. Note storage requirements. Some products require refrigeration; others are shelf-stable. 5. Be cautious of multi-strain products without evidence. While some tested multi-strain combinations are effective, many commercial products contain untested combinations. An analysis of 48 multi-strain products found that 12.5% were missing one or more listed strains, and 16 included unlisted strains (including one containing E. coli) [119].

Safety and Side Effects

General Safety Profile

Many probiotic strains derive from species with a long history of safe use in foods or from microorganisms that naturally colonize healthy GI tracts. Common probiotics — Bifidobacterium and members of the Lactobacillaceae family — are unlikely to cause harm in healthy people [2]. Side effects are usually minor and consist of self-limited gastrointestinal symptoms, primarily increased gas, which tends to resolve within a few days of continued use [2][12].

Serious Adverse Events

In rare cases, probiotic use has caused bacteremia, fungemia, or serious infections, almost exclusively in individuals who were severely ill, immunocompromised, enterically fed, or had central venous catheters [120][121]:

• Lactobacillus bacteremia: A retrospective analysis of 22,174 ICU patients found that those receiving LGG (typically through a feeding tube) had a markedly higher risk of developing Lactobacillus bacteremia — 6 confirmed cases among 522 LGG recipients versus 2 among 21,652 non-recipients [122]. Population monitoring in Finland after LGG was introduced to dairy products in 1990 showed no increase in Lactobacillus bacteremia rates through 2000 in the general population [123].
• Saccharomyces fungemia: At least 60 reports since 1966 of fungemia associated with S. cerevisiae/S. boulardii probiotic use. In many cases, patients were in ICUs, receiving enteral/parenteral nutrition, had central venous catheters, or were on broad-spectrum antimicrobials [124]. Capsules or packets containing these probiotics should not be opened near patients with central lines, and healthcare workers should change gloves after handling them [12].
• Bacillus subtilis: Has caused bacteremia and sepsis in people with compromised immune systems due to cancer [125][126].
• Enterococcus faecium: Has caused serious infections in immunocompromised individuals through physical contact (wounds, urinary catheters) [127][128].
• Contamination risk in premature infants: In 2014, a premature infant given probiotic powder died from mucormycosis (a fungal infection) caused by contaminating mold (Rhizopus oryzae), prompting the FDA to issue a general warning about fungal infection risk from probiotics in immunocompromised patients [116].
• Fatal endocarditis: A 36-year-old woman with alcoholic cirrhosis, colitis, and a pre-existing heart abnormality died from endocarditis caused by recurring L. rhamnosus bacteremia after taking a commercial probiotic containing L. acidophilus, L. rhamnosus, and S. cerevisiae for two months [129].

Abdominal Surgery

Giving a probiotic around the time of major abdominal surgery (colorectal or liver resection) may increase hospital readmission rates. In one study, patients given VSL#3 (one capsule before surgery, then twice daily up to 15 doses before discharge) were more likely to be readmitted within 30 days (16.4% vs 4.4%) due to dehydration from diet intolerance and/or diarrhea. Readmission rates remained significantly higher at 60 days (19.4% vs 5.9%). The probiotic did not increase survival or reduce post-operative infections [130].

Allergic Reactions

• Milk allergies: Probiotics containing lactose-fermenting bacteria (Lactobacillus, Bifidobacterium) are typically grown on media containing milk-derived nutrients and may contain residual milk proteins even if labeled as dairy-free [12].
• Yeast allergies: S. cerevisiae and S. boulardii should not be taken by people with yeast allergies. Cases of allergic rash and rare gastrointestinal allergic reactions have been reported [131][132].
• Prebiotic allergies: Rarely, anaphylaxis has been reported with inulin (a prebiotic). People allergic to artichoke may be at higher risk [133].

Eosinophilic Syndrome

Two cases of severe eosinophilic syndrome (an autoimmune disease) were reported in 2012 following use of an "extra strength concentration" probiotic supplement. Both patients developed sudden-onset weakness, numbness, and malaise 2-4 weeks after starting the supplement, required IV corticosteroids and immunosuppressive therapy, and suffered permanent motor and sensory deficits [134].

Special Populations

• Immunocompromised individuals: The WGO advises restricting probiotic use to strains and indications with proven efficacy [2].
• Preterm infants: FDA has raised safety concerns; use only under medical supervision with quality-assured products [116].
• HIV-positive adults: Have taken probiotics for up to 3 weeks without reported side effects [12].
• Pregnant and breastfeeding women: Certain strains have been used safely during pregnancy and lactation in multiple RCTs (e.g., LGG, L. rhamnosus HN001), but general safety data is limited. Kombucha should be avoided during pregnancy due to alcohol content and contamination risk.

Drug Interactions

Known Interactions

• Antibiotics: Can kill probiotic organisms, reducing their effectiveness. Separate probiotic and antibiotic doses by at least 2 hours [12].
• Saccharomyces cerevisiae (Brewer's yeast) and S. boulardii: Should not be taken with meperidine (Demerol) or MAO inhibitors, as this combination may cause dangerously high blood pressure [135][136].
• Blood sugar-lowering medications: Some evidence from animal studies suggests kombucha may have blood sugar-lowering effects; use with caution in people with diabetes or those taking blood sugar-lowering medication [137].
• Immunosuppressants: Individuals on immunosuppressive therapy should consult their physician before taking probiotics, as the risk of opportunistic infection from probiotic organisms is elevated in this population [2].

Vitamins and Minerals

There is no good clinical evidence that concurrent probiotic and vitamin/mineral supplementation affects the absorption or effects of either, despite some preliminary studies suggesting otherwise [12]. The only practical concern is calcium absorption — because dairy probiotics (yogurt, kefir) contain significant calcium, avoid taking additional calcium supplements simultaneously [12].

Dietary Sources

Fermented Foods Containing Live Cultures

Food	Key Organisms	Probiotic Status	Notes
Yogurt (with "live and active cultures")	L. bulgaricus, S. thermophilus, sometimes Bifidobacterium and other added strains	Potentially probiotic (depends on strains)	Look for "live and active cultures" on label. Avoid products treated after culturing [20].
Kefir	Diverse lactic acid bacteria and yeasts	Potentially probiotic	Contains wider microbial diversity than yogurt
Kimchi	Various lactic acid bacteria	Contains live cultures, not proven probiotic	Fermented cabbage dish; microbial content varies [21]
Sauerkraut (unpasteurized)	Various lactic acid bacteria	Contains live cultures, not proven probiotic	Must be unpasteurized to contain live organisms
Miso	Various bacteria and fungi	Contains live cultures, not proven probiotic	Fermented soybean paste [21]
Kombucha	Various bacteria and yeasts	Contains live cultures, not proven probiotic	See safety considerations in Section 2
Some cheeses	Various bacteria	Contains live cultures, not proven probiotic	Not all cheeses contain live cultures

Practical Notes

• Fermented foods that are heated after fermentation (sourdough bread, pasteurized sauerkraut, most commercial pickles) do not contain live organisms [20].
• Yogurt starter cultures (L. bulgaricus and S. thermophilus) were once thought unable to survive stomach acid, but newer research suggests they can survive GI transit, produce lactic acid that limits pathogenic bacteria, and help convert lactose into lactic acid, improving dairy tolerance for lactose-intolerant individuals [12].
• A food-first approach that includes regular consumption of fermented foods is reasonable for general gut health, but for specific therapeutic effects, targeted supplementation with strains that have clinical evidence is more appropriate.

Dr Brad Stanfield's MicroVitamin+ Powder includes 2.5 g of psyllium husk — a prebiotic soluble fiber that feeds beneficial gut bacteria and supports digestive health. While not a probiotic itself, prebiotic fiber provides substrate for beneficial microorganisms already present in the gut, complementing any probiotic supplementation strategy.

References

[1] Hill C, Guarner F, Reid G, et al. "The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic." Nat Rev Gastroenterol Hepatol. 2014;11:506-14. https://pubmed.ncbi.nlm.nih.gov/24912386/

[2] Guarner F, Sanders ME, Szajewska H, Cohen H, et al. "World Gastroenterology Organisation Global Guidelines: Probiotics and prebiotics." World Gastroenterology Organisation, 2023:1-52.

[3] Gibson GR, Hutkins R, Sanders ME, et al. "Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics." Nat Rev Gastroenterol Hepatol. 2017;14:491-502. https://pubmed.ncbi.nlm.nih.gov/28611480/

[4] Salminen S, Collado MC, Endo A, et al. "The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics." Nat Rev Gastroenterol Hepatol. 2021;18:649-67. https://pubmed.ncbi.nlm.nih.gov/33948025/

[5] Zmora N, Zilberman-Schapira G, Suez J, et al. "Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features." Cell. 2018;174:1388-405.e21. https://pubmed.ncbi.nlm.nih.gov/30193112/

[6] Sanders ME. "Probiotics in 2015: their scope and use." J Clin Gastroenterol. 2015;49 Suppl 1:S2-6. https://pubmed.ncbi.nlm.nih.gov/26447958/

[7] Sanders ME. "Clinical use of probiotics: what physicians need to know." Am Fam Physician. 2008;78:1026.

[8] Zheng J, Wittouck S, Salvetti E, et al. "A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae." Int J Syst Evol Microbiol. 2020;70:2782-858. https://pubmed.ncbi.nlm.nih.gov/32293557/

[9] McFarland LV. "Efficacy of Single-Strain Probiotics Versus Multi-Strain Mixtures: Systematic Review of Strain and Disease Specificity." Dig Dis Sci. 2021. https://doi.org/10.1007/s10620-020-06244-z

[10] Office of Dietary Supplements, NIH. "Dietary Supplement Label Database." 2025.

[11] O'Mahony L, et al. "Lactobacillus and Bifidobacterium in irritable bowel syndrome." Gastroenterology. 2005.

[12] ConsumerLab. "Probiotic Supplements Review." Accessed 2026. https://www.consumerlab.com/reviews/probiotic-supplements/probiotics/

[13] Food and Drug Administration. "Policy regarding quantitative labeling of dietary supplements containing live microbials: Guidance for industry." 2018.

[14] International Probiotics Association. "Best practices document for probiotics." 2017.

[15] International Scientific Association for Probiotics and Prebiotics. "Deciphering a probiotic label." 2022.

[16] Del Piano M, et al. "The use of probiotics in healthy volunteers with evacuation disorders and hard stools." J Clin Gastroenterol. 2010.

[17] Del Piano M, et al. "Correlation between chronic treatment with proton pump inhibitors and bacterial overgrowth in the stomach." Gut Microbes. 2011.

[18] Tompkins TA, et al. "The impact of meals on a probiotic during transit through a model of the human upper gastrointestinal tract." Benef Microbes. 2011.

[19] Polo A, et al. "Survival of Bacillus coagulans GBI-30 in hot beverages." J Funct Food. 2022.

[20] Marco ML, Sanders ME, Ganzle M, et al. "The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on fermented foods." Nat Rev Gastroenterol Hepatol. 2021;18:196-208. https://pubmed.ncbi.nlm.nih.gov/33398111/

[21] Hogan DE, Ivanina EA, Robbins DH. "Probiotics: a review for clinical use." Gastroenterology & Endoscopy News. 2018:1-7.

[22] Mohsen H, et al. "Alcohol content in commercial kombucha beverages." Food Analytic Methods. 2017.

[23] Holbourn A, et al. "Kombucha-related illness." BMJ Case Reports. 2017.

[24] Lind L, et al. "Erosive potential of kombucha on dental enamel." Acta Odontol Scand. 2023.

[25] Raish M, et al. "Persistence of probiotics in the gastrointestinal tract." Appl Environ Microbiol. 2006.

[26] Kullen MJ, et al. "Use of the DNA sequence of variable regions of the 16S rRNA gene for rapid and accurate identification of bacteria in the Lactobacillus acidophilus complex." J Nutr. 1997.

[27] Staudacher HM, Whelan K. "Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low FODMAP diet." Proc Nutr Soc. 2016;75:306-18. https://pubmed.ncbi.nlm.nih.gov/27268169/

[28] Zhuang X, Xiong L, Li L, et al. "Alterations of gut microbiota in patients with irritable bowel syndrome: A systematic review and meta-analysis." J Gastroenterol Hepatol. 2017;32:28-38. https://pubmed.ncbi.nlm.nih.gov/27300149/

[29] Ford AC, Quigley EM, Lacy BE, et al. "Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis." Am J Gastroenterol. 2014;109:1547-61. https://pubmed.ncbi.nlm.nih.gov/25070051/

[30] Didari T, Mozaffari S, Nikfar S, Abdollahi M. "Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis." World J Gastroenterol. 2015;21:3072-84. https://pubmed.ncbi.nlm.nih.gov/25780308/

[31] Lorenzo-Zuniga V, Llop E, Suarez C, et al. "I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life." World J Gastroenterol. 2014;20:8709-16. https://pubmed.ncbi.nlm.nih.gov/25024629/

[32] Williams EA, Stimpson J, Wang D, et al. "Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study." Aliment Pharmacol Ther. 2009;29:97-103. https://pubmed.ncbi.nlm.nih.gov/18785988/

[33] Ortiz-Lucas M, Tobias A, Saz P, Sebastian JJ. "Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis." Rev Esp Enferm Dig. 2013;105:19-36. https://pubmed.ncbi.nlm.nih.gov/23548007/

[34] Whorwell PJ, et al. "Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome." Am J Gastroenterol. 2006.

[35] Sisson G, et al. "Randomised clinical trial: a liquid multi-strain probiotic vs placebo in the irritable bowel syndrome." Aliment Pharmacol Ther. 2014.

[36] Kim HJ, et al. "A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome." Aliment Pharmacol Ther. 2003.

[37] de Chambrun GP, et al. "A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome." Dig Liver Dis. 2014.

[38] Majeed M, et al. "Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome." Nutr J. 2016.

[39] Ruggiero P. "Use of probiotics in the fight against Helicobacter pylori and IBS in children." J Clin Gastroenterol. 2010.

[40] Romano C, et al. "Lactobacillus reuteri in children with functional abdominal pain." J Paediatr Child Health. 2010.

[41] Silverman MA, Konnikova L, Gerber JS. "Impact of antibiotics on necrotizing enterocolitis and antibiotic-associated diarrhea." Gastroenterol Clin North Am. 2017;46:61-76. https://pubmed.ncbi.nlm.nih.gov/28164852/

[42] Blaabjerg S, Artzi DM, Aabenhus R. "Probiotics for the prevention of antibiotic-associated diarrhea in outpatients — a systematic review and meta-analysis." Antibiotics (Basel). 2017;6. https://pubmed.ncbi.nlm.nih.gov/29023420/

[43] Ki Cha B, Mun Jung S, Hwan Choi C, et al. "The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome." J Clin Gastroenterol. 2012;46:220-7. https://pubmed.ncbi.nlm.nih.gov/22157240/

[44] Jafarnejad S, Shab-Bidar S, Speakman JR, et al. "Probiotics reduce the risk of antibiotic-associated diarrhea in adults (18-64 years) but not the elderly (>65 years): a meta-analysis." Nutr Clin Pract. 2016;31:502-13. https://pubmed.ncbi.nlm.nih.gov/26962055/

[45] Szajewska H, Kolodziej M. "Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults." Aliment Pharmacol Ther. 2015;42:1149-57. https://pubmed.ncbi.nlm.nih.gov/26365389/

[46] Szajewska H, Kolodziej M. "Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea." Aliment Pharmacol Ther. 2015;42:793-801. https://pubmed.ncbi.nlm.nih.gov/26216624/

[47] Gao XW, et al. "Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea." Am J Gastroenterol. 2010.

[48] Ouwehand AC, et al. "Specific probiotics alleviate allergic rhinitis during the birch pollen season." Vaccine. 2013.

[49] Kabbani TA, et al. "Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate on the gut microbiota." Gut Microbes. 2017.

[50] Evans M, et al. "Effectiveness of Lactobacillus helveticus and Lactobacillus rhamnosus for the management of antibiotic-associated diarrhoea in healthy adults." Br J Nutr. 2016.

[51] Szajewska H, Berni Canani R, Domellof M, et al. "Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications." J Pediatr Gastroenterol Nutr. 2023;76:232-47. https://pubmed.ncbi.nlm.nih.gov/36219218/

[52] Suez J, et al. "Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT." Cell. 2018.

[53] Avena-Woods C. "Overview of atopic dermatitis." Am J Manag Care. 2017;23:S115-S23. https://pubmed.ncbi.nlm.nih.gov/28978208/

[54] Li L, Han Z, Niu X, et al. "Probiotic Supplementation for Prevention of Atopic Dermatitis in Infants and Children: A Systematic Review and Meta-analysis." Am J Clin Dermatol. 2019;20:367-77. https://pubmed.ncbi.nlm.nih.gov/30465329/

[55] Szajewska H, Horvath A. "Lactobacillus rhamnosus GG in the primary prevention of eczema in children: a systematic review and meta-analysis." Nutrients. 2018;10. https://pubmed.ncbi.nlm.nih.gov/30304847/

[56] Huang R, Ning H, Shen M, et al. "Probiotics for the treatment of atopic dermatitis in children: a systematic review and meta-analysis of randomized controlled trials." Front Cell Infect Microbiol. 2017;7:392. https://pubmed.ncbi.nlm.nih.gov/28932705/

[57] Zhao M, Shen C, Ma L. "Treatment efficacy of probiotics on atopic dermatitis, zooming in on infants: a systematic review and meta-analysis." Int J Dermatol. 2018;57:635-41. https://pubmed.ncbi.nlm.nih.gov/29633267/

[58] Makrgeorgou A, Leonardi-Bee J, Bath-Hextall FJ, et al. "Probiotics for treating eczema." Cochrane Database Syst Rev. 2018;11:CD006135. https://pubmed.ncbi.nlm.nih.gov/30480774/

[59] Partty A, et al. "Probiotic Lactobacillus rhamnosus GG therapy and microbiological programming in infantile colic: a randomized, controlled trial." Pediatr Res. 2015.

[60] Wickens K, et al. "Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years." Pediatr Allergy Immunol. 2018.

[61] Guarino A, Ashkenazi S, Gendrel D, et al. "European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children." J Pediatr Gastroenterol Nutr. 2014;59:132-52. https://pubmed.ncbi.nlm.nih.gov/24739189/

[62] Collinson S, Deans A, Padua-Zamora A, et al. "Probiotics for treating acute infectious diarrhoea." Cochrane Database Syst Rev. 2020;12:CD003048. https://pubmed.ncbi.nlm.nih.gov/33295643/

[63] Caffarelli C, Cardinale F, Povesi-Dascola C, et al. "Use of probiotics in pediatric infectious diseases." Expert Rev Anti Infect Ther. 2015;13:1517-35. https://pubmed.ncbi.nlm.nih.gov/26496228/

[64] Szajewska H, Skorka A, Ruszczynski M, Gieruszczak-Bialek D. "Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children — updated analysis of randomised controlled trials." Aliment Pharmacol Ther. 2013;38:467-76. https://pubmed.ncbi.nlm.nih.gov/23841880/

[65] Feizizadeh S, Salehi-Abargouei A, Akbari V. "Efficacy and safety of Saccharomyces boulardii for acute diarrhea." Pediatrics. 2014;134:e176-91.

[66] Freedman SB, Williamson-Urquhart S, Farion KJ, et al. "Multicenter Trial of a Combination Probiotic for Children with Gastroenteritis." N Engl J Med. 2018;379:2015-26. https://pubmed.ncbi.nlm.nih.gov/30462939/

[67] Schnadower D, Tarr PI, Casper TC, et al. "Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children." N Engl J Med. 2018;379:2002-14. https://pubmed.ncbi.nlm.nih.gov/30462938/

[68] Su GL, Ko CW, Bercik P, et al. "AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders." Gastroenterology. 2020;159:697-705. https://pubmed.ncbi.nlm.nih.gov/32531292/

[69] Hilton E, et al. "Efficacy of Lactobacillus GG as a diarrheal preventive in travelers." J Travel Med. 1997.

[70] Kollaritsch H, et al. "Prevention of traveler's diarrhea with Saccharomyces boulardii." Travel Med Int. 1993.

[71] Kaur L, Gordon M, Baines PA, et al. "Probiotics for induction of remission in ulcerative colitis." Cochrane Database Syst Rev. 2020;3:CD005573. https://pubmed.ncbi.nlm.nih.gov/32128795/

[72] Iheozor-Ejiofor Z, Kaur L, Gordon M, et al. "Probiotics for maintenance of remission in ulcerative colitis." Cochrane Database Syst Rev. 2020;3:CD007443. https://pubmed.ncbi.nlm.nih.gov/32128794/

[73] Lamb CA, Kennedy NA, Raine T, et al. "British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults." Gut. 2019;68:s1-s106. https://pubmed.ncbi.nlm.nih.gov/31562236/

[74] Tsai CC, Lin PP, Hsieh YM, et al. "Cholesterol-lowering potentials of lactic acid bacteria based on bile-salt hydrolase activity." ScientificWorldJournal. 2014;2014:690752. https://pubmed.ncbi.nlm.nih.gov/25574483/

[75] Kumar R, Grover S, Batish VK. "Bile salt hydrolase activity screening of lactobacilli." Probiotics Antimicrob Proteins. 2012;4:162-72.

[76] Ishimwe N, Daliri EB, Lee BH, et al. "The perspective on cholesterol-lowering mechanisms of probiotics." Mol Nutr Food Res. 2015;59:94-105. https://pubmed.ncbi.nlm.nih.gov/25521462/

[77] Cho YA, Kim J. "Effect of probiotics on blood lipid concentrations: a meta-analysis of randomized controlled trials." Medicine (Baltimore). 2015;94:e1714. https://pubmed.ncbi.nlm.nih.gov/26469906/

[78] Shimizu M, Hashiguchi M, Shiga T, et al. "Meta-analysis: effects of probiotic supplementation on lipid profiles in normal to mildly hypercholesterolemic individuals." PLoS One. 2015;10:e0139795. https://pubmed.ncbi.nlm.nih.gov/26473340/

[79] Sun J, Buys N. "Effects of probiotics consumption on lowering lipids and CVD risk factors: a systematic review and meta-analysis of randomized controlled trials." Ann Med. 2015;47:430-40. https://pubmed.ncbi.nlm.nih.gov/26340330/

[80] Khalesi S, Bellissimo N, Vandelanotte C, et al. "A review of probiotic supplementation in healthy adults: helpful or hype?" Eur J Clin Nutr. 2019;73:24-37. https://pubmed.ncbi.nlm.nih.gov/30487558/

[81] Jones ML, et al. "Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242." Eur J Clin Nutr. 2012.

[82] Nabavi S, et al. "Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease." J Dairy Sci. 2014.

[83] Ahn HY, et al. "Two Lactobacillus strains, L. curvatus HY7601 and L. plantarum KY1032, reduce cholesterol and modulate gut microbiota." Atherosclerosis. 2015.

[84] Mikelsaar M, et al. "Regulation of plasma lipid profile by Lactobacillus fermentum ME-3." BMC Nutrition. 2015.

[85] Davis CD. "The gut microbiome and its role in obesity." Nutr Today. 2016;51:167-74. https://pubmed.ncbi.nlm.nih.gov/27795585/

[86] Kadooka Y, Sato M, Ogawa A, et al. "Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial." Br J Nutr. 2013;110:1696-703. https://pubmed.ncbi.nlm.nih.gov/23614897/

[87] Kadooka Y, et al. "Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies." Eur J Clin Nutr. 2010.

[88] Sanchez M, Darimont C, Drapeau V, et al. "Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women." Br J Nutr. 2014;111:1507-19. https://pubmed.ncbi.nlm.nih.gov/24299712/

[89] Minami J, et al. "Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies." J Nutr Sci. 2015.

[90] Crovesy L, Ostrowski M, Ferreira D, et al. "Effect of Lactobacillus on body weight and body fat in overweight subjects: a systematic review of randomized controlled clinical trials." Int J Obes (Lond). 2017;41:1607-14. https://pubmed.ncbi.nlm.nih.gov/28792488/

[91] Borgeraas H, Johnson LK, Skattebu J, et al. "Effects of probiotics on body weight, body mass index, fat mass and fat percentage in subjects with overweight or obesity: a systematic review and meta-analysis of randomized controlled trials." Obes Rev. 2018;19:219-32. https://pubmed.ncbi.nlm.nih.gov/29047207/

[92] Suzumura EA, Bersch-Ferreira AC, Torreglosa CR, et al. "Effects of oral supplementation with probiotics or synbiotics in overweight and obese adults: a systematic review and meta-analyses of randomized trials." Nutr Rev. 2019;77:430-50. https://pubmed.ncbi.nlm.nih.gov/31087067/

[93] Dror T, Dickstein Y, Dubourg G, Paul M. "Microbiota manipulation for weight change." Microb Pathog. 2017;106:146-61. https://pubmed.ncbi.nlm.nih.gov/26792677/

[94] Berggren A, et al. "Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections." Eur J Nutr. 2011.

[95] Ahren IL, et al. "Evaluation of the efficacy of Lactobacillus plantarum HEAL9 and Lactobacillus paracasei 8700:2 on aspects of common cold infections in adults." J Nutr. 2020.

[96] Leyer GJ, et al. "Probiotic effects on cold and influenza-like symptom incidence and duration in children." Pediatrics. 2009.

[97] Gerasimov SV, et al. "Role of short-term use of L. acidophilus DDS-1 and B. lactis UABLA-12 in acute respiratory infections in children." Eur J Clin Nutr. 2015.

[98] Di Pierro F, et al. "Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis." Drug Healthc Patient Saf. 2014.

[99] Messaoudi M, et al. "Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects." Br J Nutr. 2011.

[100] Steenbergen L, et al. "A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood." Brain Behav Immun. 2015.

[101] Pascual J, et al. "Dietary triggers and migraine." Cephalalgia. 2010.

[102] National Headache Foundation. "Diet and Headache." 2007.

[103] Tursi A, et al. "Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease." Aliment Pharmacol Ther. 2013.

[104] Petruzziello C, et al. "The efficacy of a mix of three probiotic strains in reducing abdominal pain and inflammatory biomarkers in acute uncomplicated diverticulitis." Int J Colorectal Dis. 2019.

[105] Reid G, et al. "Oral use of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 significantly alters vaginal flora." FEMS Immunol Med Microbiol. 2003.

[106] Teughels W, et al. "Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis." J Clin Periodontol. 2013.

[107] Arroyo R, et al. "Treatment of infectious mastitis during lactation: antibiotics versus oral administration of Lactobacilli isolated from breast milk." Clin Infect Dis. 2010.

[108] Costa DJ, et al. "Efficacy of the probiotic Lactobacillus paracasei LP-33 in allergic rhinitis." Eur J Clin Nutr. 2014.

[109] Working Group of the National Advisory Council of Child Health and Human Development. "Necrotizing Enterocolitis (NEC) in Preterm Infants, Report to Secretary, Department of Health and Human Services." 2024.

[110] Shaw AG, Sim K, Rose G, et al. "Premature neonatal gut microbial community patterns supporting an epithelial TLR-mediated pathway for necrotizing enterocolitis." BMC Microbiol. 2021;21:225. https://pubmed.ncbi.nlm.nih.gov/34340678/

[111] Lai Z, Gong F. "Protective Effects of Lactobacillus reuteri on Intestinal Barrier Function in a Mouse Model of Neonatal Necrotizing Enterocolitis." Am J Perinatol. 2024;41:e386-e93. https://pubmed.ncbi.nlm.nih.gov/35390784/

[112] Blackwood BP, Yuan CY, Wood DR, et al. "Probiotic Lactobacillus Species Strengthen Intestinal Barrier Function and Tight Junction Integrity in Experimental Necrotizing Enterocolitis." J Probiotics Health. 2017;5. https://pubmed.ncbi.nlm.nih.gov/29104919/

[113] Wang Y, Florez ID, Morgan RL, et al. "Probiotics, Prebiotics, Lactoferrin, and Combination Products for Prevention of Mortality and Morbidity in Preterm Infants: A Systematic Review and Network Meta-Analysis." JAMA Pediatr. 2023;Oct 2:e233849. https://pubmed.ncbi.nlm.nih.gov/37782497/

[114] Sharif S, Meader N, Oddie SJ, et al. "Probiotics to prevent necrotizing enterocolitis in very preterm infants or very low birth weight infants." Cochrane Database Syst Rev. 2023:CD005496. https://pubmed.ncbi.nlm.nih.gov/37339767/

[115] Darmstadt GL, Al Jaifi NH, Arif S, et al. "New World Health Organization recommendations for care of preterm or low birth weight infants: health policy." eClinicalMedicine. 2023;63. https://pubmed.ncbi.nlm.nih.gov/37731901/

[116] U.S. Food and Drug Administration. "FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants." 2023.

[117] Compare D, et al. "Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome." Dig Liver Dis. 2015.

[118] Osterlund P, et al. "Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer." Br J Cancer. 2007.

[119] Gundogdu A, et al. "Genetic characterization of commercial multi-strain probiotic supplements." Mol Nutr Food Res. 2024.

[120] Didari T, Solki S, Mozaffari S, et al. "A systematic review of the safety of probiotics." Expert Opin Drug Saf. 2014;13:227-39. https://pubmed.ncbi.nlm.nih.gov/24405164/

[121] Hempel S, Newberry S, Ruelaz A, et al. "Safety of probiotics used to reduce risk and prevent or treat disease." Evid Rep Technol Assess (Full Rep). 2011:1-645. https://pubmed.ncbi.nlm.nih.gov/23126627/

[122] Yellin I, Flett KB, Merakou C, et al. "Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients." Nat Med. 2019;25:1728-32. https://pubmed.ncbi.nlm.nih.gov/31700189/

[123] Salminen MK, Tynkkynen S, Rautelin H, et al. "Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland." Clin Infect Dis. 2002;35:1155-60. https://pubmed.ncbi.nlm.nih.gov/12410474/

[124] Munoz P, Bouza E, Cuenca-Estrella M, et al. "Saccharomyces cerevisiae fungemia: an emerging infectious disease." Clin Infect Dis. 2005;40:1625-34. https://pubmed.ncbi.nlm.nih.gov/15889360/

[125] Richard V, et al. "Bacteremia due to Bacillus species." Eur J Clin Microbiol Infect Dis. 1988.

[126] Oggioni MR, et al. "Bacillus subtilis in septicemia." J Clin Microbiol. 1998.

[127] Thomas DFM, et al. "Enterococcal infection and the nervous system." J Neurol Neurosurg Psychiatry. 1991.

[128] Selleck EM, et al. "Making it stick: trends in biofilm research." Microbiol Spectr. 2019.

[129] Naqvi SSB, et al. "Probiotic related Lactobacillus rhamnosus endocarditis in a patient with liver cirrhosis." IDCases. 2018.

[130] Franko J, et al. "Probiotic supplementation in colorectal surgery and liver resection." J Am Coll Surg. 2019.

[131] Kartal O, et al. "Allergic reaction to Saccharomyces boulardii." Clin Transl Allergy. 2014.

[132] Kelesidis T, et al. "Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders." Therap Adv Gastroenterol. 2012.

[133] Gay-Crosier F, et al. "Anaphylaxis from inulin in vegetables and processed food." N Engl J Med. 2000.

[134] Mendoza FA, et al. "Eosinophilic syndrome associated with probiotic use." Case Reports Rheum. 2012.

[135] Zisook S. "A clinical note on the dietary and medication interactions of Saccharomyces." Psychosomatics. 1985.

[136] Brown CS, et al. "Drug and dietary interactions involving Saccharomyces." Ann Pharmacother. 1988.

[137] Aloulou A, et al. "Hypoglycemic and antilipidemic properties of kombucha tea in alloxan-induced diabetic rats." BMC Complement Altern Med. 2012.